EDSA — Edesa Biotech Income Statement
0.000.00%
Last trade - 00:00- $16.59m
- $13.45m
- 24
- 15
- 37
- 13
Annual income statement for Edesa Biotech, fiscal year end - September 30th, USD millions except per share, conversion factor applied.
2020 September 30th | 2021 September 30th | 2022 September 30th | 2023 September 30th | 2024 September 30th | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0.329 | 0 | 0 | 0 | 0 |
| Cost of Revenue | |||||
| Gross Profit | 0.311 | 0 | — | — | — |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Total Operating Expenses | 6.73 | 23.7 | 18.4 | 9.22 | 7.01 |
| Operating Profit | -6.4 | -23.7 | -18.4 | -9.22 | -7.01 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -6.36 | -13.3 | -17.5 | -8.37 | -6.17 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -6.36 | -13.3 | -17.5 | -8.37 | -6.17 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -6.36 | -13.3 | -17.5 | -8.37 | -6.17 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -6.36 | -13.3 | -17.5 | -8.37 | -6.17 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -5.18 | -7.73 | -7.37 | -2.93 | -1.93 |